Department of Emergency Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Copyright © 2019 The Korean Society of Critical Care Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTIONS
Conceptualization: WYK. Data curation: SMJ, YJK. Formal analysis: YJK, SMR. Methodology: SMR, WYK. Project administration: WYK. Visualization: SMJ, YJK. Writing - original draft: SMJ. Writing - review & editing: WYK.
Treatment | Total cohort (n=2,265) | Hb ≥9.0 g/dl (n=1,808) | Hb 8.0−8.9 g/dl (n=217) | Hb 7.0−7.9 g/dl (n=135) | Hb<7.0 g/dl (n=105) | P-value |
---|---|---|---|---|---|---|
Fluid resuscitation <3 hr | 1,630 (72.0) | 1,302 (72.1) | 156 (71.9) | 98 (72.6) | 74 (70.5) | 0.985 |
Antibiotic administration <3 hr | 1,479 (65.3) | 1,171 (64.8) | 141 (65.0) | 95 (70.4) | 72 (68.6) | 0.525 |
Vasopressor use | 2,001 (88.4) | 1,597 (88.4) | 193 (88.9) | 121 (89.6) | 90 (85.7) | 0.802 |
Central line insertion <6 hr | 1,382 (61.0) | 1,110 (61.4) | 125 (57.6) | 90 (66.7) | 57 (54.3) | 0.172 |
Mechanical ventilator | 628 (27.7) | 498 (27.5) | 64 (29.5) | 29 (21.5) | 37 (35.2) | 0.114 |
Renal replacement therapy <24 hr | 209 (9.2) | 172 (9.5) | 16 (7.4) | 8 (5.9) | 13 (12.4) | 0.254 |
Transfusion <6 hr | ||||||
pRBC | 174 (7.7) | 28 (1.5) | 31 (14.3) | 45 (33.3) | 70 (66.7) | <0.001 |
FFP | 99 (4.4) | 58 (3.2) | 11 (5.1) | 10 (7.4) | 20 (19.0) | <0.001 |
PC | 144 (6.4) | 59 (3.3) | 31 (14.3) | 18 (13.3) | 36 (34.3) | <0.001 |
Outcome | ||||||
28-Day mortalitya | 452 (21.1) | 325 (19.1) | 56 (27.3) | 35 (26.7) | 36 (35.0) | <0.001 |
90-Day mortalityb | 612 (32.5) | 433 (29.1) | 80 (43.0) | 53 (46.5) | 46 (46.9) | <0.001 |
Values are presented as number (%).
Hb: hemoglobin; pRBC: packed red blood cell; FFP: fresh frozen plasma; PC: platelet concentrates.
aA total of 126 patients (108 in Hb ≥9.0 g/dl, 12 in Hb 8.0−8.9 g/dl, 4 in Hb 7.0−7.9 g/dl, and 2 in Hb <7.0 g/dl) were lost to follow-up;
bA total of 308 patients (267 in Hb ≥9.0 g/dl, 19 in Hb 8.0−8.9 g/dl, 16 in Hb 7.0−7.9 g/dl, and 6 in Hb <7.0 g/dl) were lost to follow-up.
Characteristics | Total cohort (n=2,265) | Hb ≥9.0 g/dl (n=1,808) | Hb 8.0−8.9 g/dl (n=217) | Hb 7.0−7.9 g/dl (n=135) | Hb <7.0 g/dl (n=105) | P-value |
---|---|---|---|---|---|---|
Age (yr) | 70.0 (60.0–78.0) | 71.0 (60.0–78.0) | 68.0 (59.0–77.0) | 69.0 (59.0–78.0) | 65.0 (55.0–72.0) | <0.001 |
Male | 1,321 (58.3) | 1,060 (58.6) | 116 (53.5) | 77 (57.0) | 68 (64.8) | 0.254 |
Comorbid disease | ||||||
Hypertension | 933 (41.2) | 762 (42.1) | 89 (41.0) | 52 (38.5) | 30 (28.6) | 0.046 |
Diabetes mellitus | 690 (30.5) | 544 (30.1) | 69 (31.8) | 41 (30.4) | 36 (34.3) | 0.795 |
Cerebrovascular accident | 278 (12.3) | 234 (12.9) | 26 (12.0) | 12 (8.9) | 6 (5.7) | 0.094 |
Chronic pulmonary disease | 180 (7.9) | 156 (8.6) | 12 (5.5) | 9 (6.7) | 3 (2.9) | 0.075 |
Chronic renal disease | 167 (7.4) | 130 (7.2) | 17 (7.8) | 15 (11.1) | 5 (4.8) | 0.265 |
Infection | 0.206 | |||||
Respiratory | 563 (24.9) | 452 (25.0) | 59 (27.2) | 32 (23.7) | 20 (19.0) | |
Urinary | 427 (18.9) | 359 (19.9) | 36 (16.6) | 17 (12.6) | 15 (14.3) | |
Gastrointestinal | 293 (12.9) | 238 (13.2) | 24 (11.1) | 21 (15.6) | 10 (9.5) | |
Hepatobiliary and pancreas | 408 (18.0) | 319 (17.6) | 42 (19.4) | 24 (17.8) | 23 (21.9) | |
Soft tissue | 61 (2.7) | 52 (2.9) | 4 (1.8) | 3 (2.2) | 2 (1.9) | |
Others | 114 (5.0) | 78 (4.3) | 16 (7.4) | 10 (7.4) | 10 (9.5) | |
Mixed | 262 (11.6) | 205 (11.3) | 24 (11.1) | 17 (12.6) | 16 (15.2) | |
Unknown | 137 (6.0) | 105 (5.8) | 12 (5.5) | 11 (8.1) | 9 (8.6) | |
Laboratoryfinding | ||||||
White blood cell count (103/µl) | 10.55 (5.37–17.15) | 11.01 (6.00–17.48) | 8.80 (3.30–14.42) | 7.90 (2.47–14.86) | 6.34 (0.64–18.40) | <0.001 |
Hemoglobin (g/dl) | 11.1 (9.3–12.8) | 11.7 (10.5–13.1) | 8.5 (8.2–8.7) | 7.6 (7.3–7.7) | 6.3 (5.6–6.6) | <0.001 |
Hematocrit (%) | 33.6 (28.6–38.4) | 35.4 (31.8–39.5) | 25.9 (25.0–26.8) | 22.8 (22.0–23.7) | 19.0 (17.0–20.7) | <0.001 |
Platelet (103/µl) | 148.0 (83.0–227.8) | 155.5 (98.0–234.0) | 105.0 (49.5–173.0) | 89.0 (40.0–194.0) | 62.0 (26.0–199.3) | <0.001 |
PT (INR) | 1.26 (1.13–1.47) | 1.24 (1.12–1.43) | 1.34 (1.17–1.58) | 1.37 (1.20–1.61) | 1.42 (1.27–1.61) | <0.001 |
Creatinine (mg/dl) | 1.34 (0.92–2.14) | 1.33 (0.92–2.13) | 1.38 (0.89–2.19) | 1.33 (0.96–2.26) | 1.30 (0.99–2.01) | 0.904 |
CRP (mg/dl) | 12.4 (4.5–21.9) | 11.92 (3.82–21.64) | 13.76 (6.32–22.12) | 13.25 (5.00–22.73) | 14.51 (7.61–23.45) | 0.035 |
CRP >0.6 mg/dl | 2,102 (92.8) | 1,674 (92.6) | 205 (94.5) | 123 (91.1) | 100 (95.2) | 0.468 |
Severity score | ||||||
SOFA score | 8.0 (6.0–11.0) | 8.0 (5.0–10.0) | 9.0 (6.0–11.0) | 9.0 (6.0–11.0) | 9.0 (6.0–12.0) | <0.001 |
APACHE II score | 19.0 (13.0–25.0) | 18.0 (13.0–24.0) | 21.0 (16.0–28.0) | 20.0 (16.0–25.0) | 24.0 (18.0–30.0) | <0.001 |
Treatment | Total cohort (n=2,265) | Hb ≥9.0 g/dl (n=1,808) | Hb 8.0−8.9 g/dl (n=217) | Hb 7.0−7.9 g/dl (n=135) | Hb<7.0 g/dl (n=105) | P-value |
---|---|---|---|---|---|---|
Fluid resuscitation <3 hr | 1,630 (72.0) | 1,302 (72.1) | 156 (71.9) | 98 (72.6) | 74 (70.5) | 0.985 |
Antibiotic administration <3 hr | 1,479 (65.3) | 1,171 (64.8) | 141 (65.0) | 95 (70.4) | 72 (68.6) | 0.525 |
Vasopressor use | 2,001 (88.4) | 1,597 (88.4) | 193 (88.9) | 121 (89.6) | 90 (85.7) | 0.802 |
Central line insertion <6 hr | 1,382 (61.0) | 1,110 (61.4) | 125 (57.6) | 90 (66.7) | 57 (54.3) | 0.172 |
Mechanical ventilator | 628 (27.7) | 498 (27.5) | 64 (29.5) | 29 (21.5) | 37 (35.2) | 0.114 |
Renal replacement therapy <24 hr | 209 (9.2) | 172 (9.5) | 16 (7.4) | 8 (5.9) | 13 (12.4) | 0.254 |
Transfusion <6 hr | ||||||
pRBC | 174 (7.7) | 28 (1.5) | 31 (14.3) | 45 (33.3) | 70 (66.7) | <0.001 |
FFP | 99 (4.4) | 58 (3.2) | 11 (5.1) | 10 (7.4) | 20 (19.0) | <0.001 |
PC | 144 (6.4) | 59 (3.3) | 31 (14.3) | 18 (13.3) | 36 (34.3) | <0.001 |
Outcome | ||||||
28-Day mortality |
452 (21.1) | 325 (19.1) | 56 (27.3) | 35 (26.7) | 36 (35.0) | <0.001 |
90-Day mortality |
612 (32.5) | 433 (29.1) | 80 (43.0) | 53 (46.5) | 46 (46.9) | <0.001 |
Characteristics | OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value |
---|---|---|---|---|
Age (yr) | 1.020 (1.012–1.028) | <0.001 | 1.027 (1.018–1.036) | <0.001 |
Female sex | 0.759 (0.622–0.926) | 0.007 | ||
Comorbid disease | ||||
Hypertension | 0.969 (0.796–1.179) | 0.752 | ||
Diabetes mellitus | 1.221 (0.995–1.500) | 0.056 | ||
Cerebrovascular accident | 1.154 (0.859–1.552) | 0.342 | ||
Chronic pulmonary disease | 1.532 (1.100–2.134) | 0.012 | 1.522 (1.072–2.161) | 0.019 |
Chronic renal disease | 1.426 (1.008–2.018) | 0.045 | ||
Laboratoryfinding | ||||
Hemoglobin (g/dl) | 0.888 (0.853–0.923) | <0.001 | ||
Hemoglobin range (g/dl) | ||||
≥9.0 | Reference | Reference | ||
8.0−8.9 | 1.835 (1.345–2.505) | <0.001 | 1.883 (1.358–2.611) | <0.001 |
7.0−7.9 | 2.113 (1.438–3.104) | <0.001 | 1.966 (1.309–2.953) | 0.001 |
<7.0 | 2.151 (1.425–3.249) | <0.001 | 2.349 (1.519–3.630) | <0.001 |
Initial SOFA score | 1.199 (1.160–1.239) | <0.001 | 1.199 (1.160–1.241) | <0.001 |
pRBC transfusion <6 hr | 0.712 (0.611–0.830) | <0.001 |
Values are presented as median (interquartile range) or number (%). Hb: hemoglobin; PT: prothrombin time; INR: international normalized ratio; CRP: C-reactive protein; SOFA: Sequential Organ Failure Assessment; APACHE: Acute Physiology and Chronic Health Evaluation.
Values are presented as number (%). Hb: hemoglobin; pRBC: packed red blood cell; FFP: fresh frozen plasma; PC: platelet concentrates. A total of 126 patients (108 in Hb ≥9.0 g/dl, 12 in Hb 8.0−8.9 g/dl, 4 in Hb 7.0−7.9 g/dl, and 2 in Hb <7.0 g/dl) were lost to follow-up; A total of 308 patients (267 in Hb ≥9.0 g/dl, 19 in Hb 8.0−8.9 g/dl, 16 in Hb 7.0−7.9 g/dl, and 6 in Hb <7.0 g/dl) were lost to follow-up.
OR: odds ratio; CI: confidence interval; SOFA: Sequential Organ Failure Assessment; pRBC: packed red blood cell.